Forgot your password?
Please enter your username or email address. Instructions for resetting the password will be immediately emailed to you.
Please note: While some information will still be current in a year, other information may already be out of date in three months time. If you are in any doubt, please feel free to ask.
Ivacaftor US
- Question
- Hello, the drug Ivacaftor is now being marketed in the United States, is it prescribed routinely to all carriers of the mutation in question? Is it going to be the same in France when it has his license?
When can we have details of the concrete effects (hopefully very beneficial) in patients and possibly talk about a therapeutic revolution if any?
- Answer
- Hello
Ivacaftor marketed in the United States may be prescribed to all patients aged 6 years and over and living in the United States with the G551D mutation.
It will be the same in France when the product receives European marketing authorization. (However the request was made in Europe for 9 other "gating" mutations. See the question and answer: ecorn-cf.eu/index.php?id=65&L=0&tx_expertadvice_pi1[showitem]=1732&tx_expertadvice_pi1[search]=)
Concerning the practical effects of the drug, we must step back and have at least one year of monitoring patients on treatment before talking about a possible therapeutic revolution.
Best regards
Anna Ronayette (Head of clinical research programs of Vaincre la mucoviscidose)
- 22.03.2012
